Synopsis:- The ₹10,000 crore Biopharma Shakti initiative aims to build a global manufacturing hub, with 3 new institutes, upgrades to 7 others, and 1,000 clinical trial centres. As the ₹4.71 lakh crore sector targets ₹11 lakh crore by 2030, several pharma stocks gained up to 4%.
Today, Union Finance Minister Nirmala Sitharaman announced an allocation of ₹10,000 crore for the Biopharma Shakti initiative over the next five years. The move aims to strengthen India’s position as a global biopharma manufacturing hub. This funding is expected to boost domestic innovation, enhance infrastructure, and encourage large-scale production of advanced pharmaceutical and biological products.
Under the Biopharma Shakti initiative, the government plans to establish a comprehensive ecosystem for the biopharmaceutical industry. The proposal includes setting up three new NIPER institutes and upgrading seven existing ones to strengthen advanced research, talent development, and industry partnerships. This move aims to enhance innovation capacity and build a skilled workforce for the sector.
Additionally, the initiative will create a nationwide network of 1,000 accredited clinical trial centres to speed up drug development and strengthen regulatory standards. This move is expected to improve research quality, attract global partnerships, and position India as a reliable and competitive hub for international clinical research and innovation.
The Pharmaceuticals sector plays a vital role in healthcare through the manufacturing, formulation, and development of medicines and biologics. With a market size of ₹4.71 lakh crore as of October 2025, the industry is projected to reach nearly ₹11 lakh crore by 2030, driven by rising healthcare awareness and demand.
India has established itself as a global pharmaceutical powerhouse, ranking third in production by volume and 14th by value. Its strength lies in cost-effective generic medicines and strong export presence across 200 countries, including highly regulated markets like the US, Western Europe, Japan, and Australia.
| Company Name | CMP | Increased % |
|---|---|---|
| Biocon Ltd | 371.35 | 2% |
| Dr Reddy’s Laboratories Ltd | 1,226.90 | 1.49% |
| Syngene International Ltd | 479.05 | 1.34% |
| Torrent Pharmaceuticals Ltd | 3,974.90 | 1.14% |
| J B Chemicals and Pharmaceuticals Ltd | 1,878.30 | 2% |
| Sun Pharmaceutical Industries Ltd | 1,622.60 | 2% |
| Mankind Pharma Ltd | 2,134.50 | 1% |
| Aurobindo Pharma Ltd | 1,195.00 | 1% |
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Sun Pharma and 6 other pharma Co. likely to benefit from ₹10,000 Cr Biopharma Shakti initiative appeared first on Trade Brains.